164 related articles for article (PubMed ID: 17958982)
21. Circulating cytokines in pulmonary tuberculosis according to HIV status and dietary iron content.
Gordeuk VR; Moyo VM; Nouraie M; Gangaidzo IT; Murphree NL; Gomo ZA; Boelaert JR; Weiss G
Int J Tuberc Lung Dis; 2009 Oct; 13(10):1267-73. PubMed ID: 19793432
[TBL] [Abstract][Full Text] [Related]
22. Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis.
Cho OH; Park KH; Kim T; Song EH; Jang EY; Lee EJ; Chong YP; Choi SH; Lee SO; Woo JH; Kim YS; Kim SH
J Infect; 2009 Jul; 59(1):56-61. PubMed ID: 19535147
[TBL] [Abstract][Full Text] [Related]
23. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis.
Jeon DS; Kim DH; Kang HS; Hwang SH; Min JH; Kim JH; Sung NM; Carroll MW; Park SK
Int J Tuberc Lung Dis; 2009 May; 13(5):594-600. PubMed ID: 19383192
[TBL] [Abstract][Full Text] [Related]
24. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain.
Anibarro L; Casas S; Paz-Esquete J; Gonzalez L; Pena A; Guerra MR; Sande D; Calviño L; Santin M;
Int J Tuberc Lung Dis; 2010 Jun; 14(6):701-7. PubMed ID: 20487607
[TBL] [Abstract][Full Text] [Related]
25. [Incidence of and factors for non-compliance to antituberculous treatment].
Cáceres Fde M; Orozco LC
Biomedica; 2007 Dec; 27(4):498-504. PubMed ID: 18320117
[TBL] [Abstract][Full Text] [Related]
26. Achieving international targets for tuberculosis treatment success among HIV-positive patients in New York City.
King L; Munsiff SS; Ahuja SD
Int J Tuberc Lung Dis; 2010 Dec; 14(12):1613-20. PubMed ID: 21144248
[TBL] [Abstract][Full Text] [Related]
27. Toxicity of first-line drugs for treatment of tuberculosis in children: review.
Frydenberg AR; Graham SM
Trop Med Int Health; 2009 Nov; 14(11):1329-37. PubMed ID: 19735381
[TBL] [Abstract][Full Text] [Related]
28. Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis.
Cheng SL; Wang HC; Yang PC
Int J Tuberc Lung Dis; 2007 Dec; 11(12):1290-5. PubMed ID: 18034948
[TBL] [Abstract][Full Text] [Related]
29. Cases of human immunodeficiency virus infection and tuberculosis--early experiences of different aspects.
Dey SK; Pal NK; Chakrabarty MS
J Indian Med Assoc; 2003 May; 101(5):291-2, 294, 296 passim. PubMed ID: 14575217
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for multidrug-resistant tuberculosis in Hong Kong.
Law WS; Yew WW; Chiu Leung C; Kam KM; Tam CM; Chan CK; Leung CC
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1065-70. PubMed ID: 18713506
[TBL] [Abstract][Full Text] [Related]
31. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
[TBL] [Abstract][Full Text] [Related]
32. Life-threatening cutaneous reactions to thiacetazone-containing antituberculosis treatment in Kumasi, Ghana.
Lawn SD; Frimpong EH; Acheampong JW
West Afr J Med; 1999; 18(4):249-53. PubMed ID: 10734785
[TBL] [Abstract][Full Text] [Related]
33. Multiforme skin lesions in Yekatit 12 Hospital, 1976-1994.
Gessesse B; Mulugeta E
Ethiop Med J; 2000 Jan; 38(1):43-7. PubMed ID: 11144879
[TBL] [Abstract][Full Text] [Related]
34. Isoniazid hepatotoxicity among drug users: the role of hepatitis C.
Fernández-Villar A; Sopeña B; Vázquez R; Ulloa F; Fluiters E; Mosteiro M; Martínez-Vázquez C; Piñeiro L
Clin Infect Dis; 2003 Feb; 36(3):293-8. PubMed ID: 12539070
[TBL] [Abstract][Full Text] [Related]
35. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
36. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors.
Narita M; Hisada M; Thimmappa B; Stambaugh J; Ibrahim E; Hollender E; Ashkin D
Clin Infect Dis; 2001 Feb; 32(3):515-7. PubMed ID: 11170964
[TBL] [Abstract][Full Text] [Related]
37. The cost to health services of human immunodeficiency virus (HIV) co-infection among tuberculosis patients in Sudan.
El-Sony AI
Health Policy; 2006 Feb; 75(3):272-9. PubMed ID: 16325960
[TBL] [Abstract][Full Text] [Related]
38. Use of Standard Therapy for Tuberculosis is Associated with Increased Adverse Reactions in Patients with HIV.
Pedral-Sampaio DB; Martins Netto E ; Alcântara AP; Souza J; Moura L; Brites C; Pedroso C; Biana JC; Badaró R
Braz J Infect Dis; 1997 Jun; 1(3):123-130. PubMed ID: 11105126
[TBL] [Abstract][Full Text] [Related]
39. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
[TBL] [Abstract][Full Text] [Related]
40. Directly observed treatment is associated with reduced default among foreign tuberculosis patients in Thailand.
Kapella BK; Anuwatnonthakate A; Komsakorn S; Moolphate S; Charusuntonsri P; Limsomboon P; Wattanaamornkiat W; Nateniyom S; Varma JK
Int J Tuberc Lung Dis; 2009 Feb; 13(2):232-7. PubMed ID: 19146753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
